Enlivex Therapeutics announced its Nasdaq listing under the symbol (ENLV) and the concurrent closing of a private placement of ordinary shares priced at $12.25 per share. Pursuant to the financing, Enlivex expects its cash balance to allow initiation of several late-stage immunotherapy clinical trials and potentially reach multiple clinical milestones through a Phase II/III trial studying prevention of complications post bone-marrow transplantations, a Phase II trial studying prevention of cytokine storms associated with sepsis and a program surrounding a proprietary “immune checkpoint” for solid cancers discovered by Enlivex. Enlivex is developing a immunotherapy candidate with a mode of action that targets clinical indications defined as “life-threatening, unmet medical need,” such as preventing or treating complications associated with bone-marrow transplantations, sepsis as well as treatment of solid tumors via immune checkpoint reprogramming, potentially increasing the efficacy of CAR-T, TCR and other anti-cancer therapies.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.